Expanding regulatory approvals, growing biologics pipelines, and escalating investment in following-technology peptide modalities go on to help make 2025 a pivotal growth calendar year with the field.CordenPharma is another big CDMO with substantial US functions, notably in Colorado. They concentrate on using peptide assignments from early-stage gr